Serum NFL as a biomarker for CIDP Diagnosis and Treatment
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Serum NFL as a biomarker for CIDP Diagnosis and Treatment
-
ナレーター：
-
著者：
このコンテンツについて
This scientific study investigated the use of serum neurofilament light chain (sNFL), particularly when adjusted for age and BMI as z-scores (zNFL), as a biomarker for chronic inflammatory demyelinating polyneuropathy (CIDP). Analyzing a large cohort of patients with immune-mediated neuropathies, the researchers found that elevated zNFL correlated with increased disease severity in patients with typical CIDP, especially in the early stages of the illness. A zNFL score above 2 in the early phase of typical CIDP was associated with more severe motor dysfunction and a lack of response to initial standard treatments, suggesting that this biomarker could help identify patients needing more aggressive, early immunotherapy and potentially distinguish between typical and atypical forms of CIDP. The study concludes by recommending sNFL measurement with z-score analysis as a valuable tool for CIDP diagnosis, assessment of severity, and treatment guidance in clinical practice.